Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 0.4%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 0.1% [1] - The CSI Biotechnology Theme Index increased by 0.1%, and the CSI Innovative Drug Industry Index rose by 0.2% [1] - The CSI 300 Pharmaceutical and Health Index saw an increase of 0.4% [1] Group 2 - The Hang Seng Innovative Drug ETF (159316) experienced a net inflow of 580 million yuan last week, bringing its total size to 2.7 billion yuan, marking a historical high [1] - The rolling price-to-earnings ratio for the pharmaceutical and health industry is reported at 33.5 times, with a valuation percentile of 63.4% [4] - The liquid products and other human biotechnology sector have a rolling price-to-earnings ratio of 64.2 times, with a valuation percentile of 85.3% [4]
港股医药板块震荡调整，关注恒生创新药ETF（159316）、港股通医药ETF（513200）等配置价值
Mei Ri Jing Ji Xin Wen·2025-09-15 14:02